BSI Congress 2025

01 - 04 December 2025 | Liverpool, UK

- BRONZE SPONSOR -

From 1–4 December 2025, the immunology community gathers at ACC Liverpool for BSI Congress 2025 — the flagship meeting of British Society for Immunology. Expect 1,500+ delegates, four intense days of plenaries, parallel sessions and poster talks covering themes from infection and immunity, autoimmunity, neuro-immune interfaces, barrier biology, to cancer immunology and immunotherapy.

As a company rooted in fluid biomarker analysis, Alamar Bioscience is uniquely positioned at the intersection of immunology and translational research. BSI Congress offers the ideal forum to explore how liquid-biopsy biomarkers (e.g. circulating immune signals, cytokines, extracellular vesicles, immune-related proteins/RNA) can inform immune status, therapy response, minimal residual disease and patient stratification.

We’re especially proud to support a presentation by our customer from University College London (UCL) on Thursday,  underscoring how Alamar’s platform helps drive real-world immunological research and contributes to breakthroughs in immune-related disease and therapy.

Visit us at Booth #23

Product Showcase

Thursday, 04 December | 13:00 - 13:15 GMT
Presentation theatre (Exhibition Hall 2)

Can we predict sustained remission in Systemic Lupus erythematosus? 

Rym Abida
Clinical Research Fellow
Aging, Rheumatology and Regenerative Medicine
University College London

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.